-+ 0.00%
-+ 0.00%
-+ 0.00%

China's First Commercial Insurance Drug List to Include Hutchmed (China)'s Tazverik

MT Newswires·12/07/2025 23:16:51
Listen to the news
11:16 PM EST, 12/07/2025 (MT Newswires) -- Hutchmed (China) (HCM.L) said Monday that China's first National Commercial Health Insurance Innovative Drug List will include its medication for relapsed or refractory follicular lymphoma, Tazverik. The biopharmaceutical company also noted that the China National Healthcare Security Administration renewed contracts for the inclusion of its Elunate, Orpathys, and Sulanda drugs in the edition of the National Reimbursement Drug List that will take effect on Jan. 1, 2026.